These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 29499662)

  • 61. Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy.
    Akutsu N; Sasaki S; Takagi H; Motoya M; Shitani M; Igarashi M; Hirayama D; Wakasugi H; Yamamoto H; Kaneto H; Yonezawa K; Yawata A; Adachi T; Hamamoto Y; Shinomura Y
    Int J Clin Oncol; 2015 Feb; 20(1):105-10. PubMed ID: 24744262
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation].
    Hu AB; He XS; Tai Q; Zhu XF; Ma Y; Wang DP; Wang GD; Wu LW; Ju WQ; Huang JF
    Zhonghua Yi Xue Za Zhi; 2012 May; 92(18):1264-7. PubMed ID: 22883065
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.
    Ziogas DC; Papadatos-Pastos D; Thillai K; Korantzis I; Chowdhury R; Suddle A; O'Grady J; Al-Khadimi G; Allen N; Heaton N; Ross PJ; Sarker D
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):48-55. PubMed ID: 27623000
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.
    Jia N; Liou I; Halldorson J; Carithers R; Perkins J; Reyes J; Yeh M; Stohr E; Rao S; Lin EH
    Anticancer Res; 2013 Jun; 33(6):2797-800. PubMed ID: 23749944
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L; Su H; Shao H; Xu K; Liang S; Liu J
    Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study.
    Naqi N; Ahmad S; Murad S; Khattak J
    Hematol Oncol Stem Cell Ther; 2014 Mar; 7(1):27-31. PubMed ID: 24333135
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience Second Analysis.
    Arizumi T; Ueshima K; Iwanishi M; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Ida H; Minami Y; Sakurai T; Nishida N; Kitano M; Kudo M
    Dig Dis; 2015 Oct; 33(6):728-34. PubMed ID: 26488730
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.
    Jeong SW; Jang JY; Shim KY; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim KH; Kim JH
    Gut Liver; 2013 Nov; 7(6):696-703. PubMed ID: 24312711
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study.
    Ganten TM; Stauber RE; Schott E; Malfertheiner P; Buder R; Galle PR; Göhler T; Walther M; Koschny R; Gerken G
    Clin Cancer Res; 2017 Oct; 23(19):5720-5728. PubMed ID: 28698202
    [No Abstract]   [Full Text] [Related]  

  • 70. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure.
    Granito A; Marinelli S; Terzi E; Piscaglia F; Renzulli M; Venerandi L; Benevento F; Bolondi L
    Dig Liver Dis; 2015 Jun; 47(6):518-22. PubMed ID: 25861840
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.
    Pressiani T; Boni C; Rimassa L; Labianca R; Fagiuoli S; Salvagni S; Ferrari D; Cortesi E; Porta C; Mucciarini C; Latini L; Carnaghi C; Banzi M; Fanello S; De Giorgio M; Lutman FR; Torzilli G; Tommasini MA; Ceriani R; Covini G; Tronconi MC; Giordano L; Locopo N; Naimo S; Santoro A
    Ann Oncol; 2013 Feb; 24(2):406-411. PubMed ID: 23041587
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function.
    Yang H; Woo HY; Lee SK; Han JW; Jang B; Nam HC; Lee HL; Lee SW; Song DS; Song MJ; Oh JS; Chun HJ; Jang JW; Lozada A; Bae SH; Choi JY; Yoon SK
    Clin Mol Hepatol; 2017 Jun; 23(2):128-137. PubMed ID: 28494528
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma.
    Li Y; Zheng YB; Zhao W; Liu B; Hu BS; He X; Huang JW; Lu LG
    Med Oncol; 2013 Dec; 30(4):730. PubMed ID: 24048774
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study.
    Wada Y; Takami Y; Matsushima H; Tateishi M; Ryu T; Yoshitomi M; Matsumura T; Saitsu H
    Intern Med; 2018 May; 57(10):1345-1353. PubMed ID: 29279513
    [TBL] [Abstract][Full Text] [Related]  

  • 76. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
    Geschwind JF; Kudo M; Marrero JA; Venook AP; Chen XP; Bronowicki JP; Dagher L; Furuse J; Ladrón de Guevara L; Papandreou C; Sanyal AJ; Takayama T; Ye SL; Yoon SK; Nakajima K; Lehr R; Heldner S; Lencioni R
    Radiology; 2016 May; 279(2):630-40. PubMed ID: 26744927
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma.
    Chen SW; Lin LC; Kuo YC; Liang JA; Kuo CC; Chiou JF
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1041-7. PubMed ID: 24661657
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
    Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
    Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
    Tai WM; Yong WP; Lim C; Low LS; Tham CK; Koh TS; Ng QS; Wang WW; Wang LZ; Hartano S; Thng CH; Huynh H; Lim KT; Toh HC; Goh BC; Choo SP
    Ann Oncol; 2016 Dec; 27(12):2210-2215. PubMed ID: 27681866
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.
    Kan X; Jing Y; Wan QY; Pan JC; Han M; Yang Y; Zhu M; Wang Q; Liu KH
    Eur Rev Med Pharmacol Sci; 2015; 19(2):247-55. PubMed ID: 25683938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.